OnKure Therapeutics, Inc. (OKUR)

Pharmaceutical Preparations · market cap $118M · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

OnKure Therapeutics (OKUR) is a clinical-stage pharmaceutical company with 46 employees and a ~$173M market cap, advancing OKI-179 in combination with binimetinib into Phase 2 for RAS-mutant cancers. The company carries no revenue and has burned approximately $215M in net losses over the past four years, though it holds $192.1M in cash providing roughly 44 months of runway.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10
2027-01-01Trial Startimp 3/10

Pipeline

Asset	Phase	Indication
OKI-179 + binimetinib	Phase 2	RAS Mutation

Price & technical context

3-month

-44.5%

6-month

-37.6%

12-month

-7.6%

52-wk range

$2.32–$5.27

vs 50-day MA

-29.2%

vs 200-day MA

-30.7%

Realized vol

69.5%

Max drawdown

-90.5%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for OKUR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.